Oncotarget

Clinical Research Papers:

Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase

Liang Wang, Hua Wang, Jing-hua Wang, Zhong-jun Xia, Yue Lu, Hui-qiang Huang, Wen-qi Jiang and Yu-jing Zhang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:30317-30326. https://doi.org/10.18632/oncotarget.4505

Metrics: PDF 903 views  |   HTML 1174 views  |   ?  


Abstract

Liang Wang1,2,*, Hua Wang1,2,*, Jing-hua Wang1,2,*, Zhong-jun Xia1,2, Yue Lu1,2, Hui-qiang Huang1,3, Wen-qi Jiang1,3, Yu-jing Zhang1,4

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People’s Republic of China

2Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China

3Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China

4Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Yu-jing Zhang, e-mail: zhangyujingsysucc@126.com

Keywords: extranodal NK/T cell lymphoma, prognosis, Epstein-Barr virus, asparaginase, minimal residual disease

Received: March 03, 2015     Accepted: June 22, 2015     Published: July 03, 2015

ABSTRACT

Circulating Epstein-Barr virus (EBV) DNA is a biomarker of EBV-associated malignancies. Its prognostic value in early stage NK/T-cell lymphoma (NKTCL) in the era of asparaginase was investigated. 68 patients were treated with a median of 4 cycles of asparaginase-based chemotherapy followed by a median of 54.6Gy (range 50–60Gy) radiation. The amount of EBV-DNA was prospectively measured in both pretreatment and post-treatment plasma samples by real-time quantitative PCR. At the end of treatment, complete response (CR) rate was 79.4%, and overall response rate (ORR) was 88.2%. Patients with negative pretreatment EBV-DNA had a higher CR rate (96.0% vs. 69.8%, p = 0.023). The 3-year progression-free survival (PFS) rate and overall survival (OS) rate was 71% and 83%, respectively. In multivariate survival analysis, post-treatment EBV-DNA positivity and treatment response (non-CR) were prognostic factors for both worse PFS and OS (p < 0.05). Local tumor invasion was also a prognostic factor for worse OS (p = 0.010). In patients with CR, post-treatment EBV-DNA positivity correlated with inferior PFS and OS (both p < 0.0001). In patients with positive pretreatment EBV-DNA, negative post-treatment EBV-DNA correlated with better PFS and OS (both p < 0.0001). These findings indicate that post-treatment EBV-DNA positivity can predict early relapse and poor prognosis for patients with early stage NKTCL in the era of asparaginase, and may be used as an indicator of minimal residual disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4505